Clinical trials: Osteoporosis, Post-Menopausal
Osteoporosis
Feasibility of Doctors' Rooms-based Infusion of Zoledronic Acid
1. The study will assess the safety and tolerability of a single-infusion of zoledronic acid 5 mg administered in a private medical practice setting by a nurse provided by a nationwide infusion service.
- Trial name
- LISA (NCT00745485)
- Testing
- zoledronic acid
- Where
- 14 sites in Australia
- Volunteers
- 186 people
- Sponsor
- Novartis Pharmaceuticals
Menopause, Osteoporosis
Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis
The purpose of this research study is to evaluate the safety and effectiveness of this investigational drug for the treatment of menopausal symptoms while protecting the endometrium (uterine lining) and preventing postmenopausal…
- Trial name
- NCT00808132
- Testing
- bazedoxifene 20 mg/ conjugated estrogens 0.45 mg, bazedoxifene 20 mg/ conjugated estrogens 0.625 mg, bazedoxifene 20 mg
- Where
- 178 sites in United States, Argentina and 10 more
- Volunteers
- 1,886 people
- Sponsor
- Pfizer
Postmenopausal Osteoporosis
Study of Bone Histomorphometry, Microarchitecture, and Matrix Structure in Patients Receiving Alendronate or Risedronate
Patients who have received the appropriate number of years of alendronate or risedronate therapy will be recruited. Each patient will have received baseline BMD measurements performed at the spine and the hip by DXA.
- Trial name
- NCT00778154
- Where
- 8 sites in United States, Canada
- Volunteers
- 105 people
- Sponsor
- Warner Chilcott
Osteoporosis, Postmenopausal
Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of MW031 and Prolia® in Healthy Adults
A randomized, double-blind and parallel group study to compare the pharmacokinetic, safety and pharmacodynamic of MW031 and Prolia® in healthy adults.
- Trial name
- MW031 (NCT04798313)
- Testing
- MW031, Prolia®
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Postmenopausal Osteoporosis
A Study of Quarterly Intravenous Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis.
This single arm study will assess the efficacy and safety of quarterly intravenous Bonviva in women with post-menopausal osteoporosis. All patients will receive Bonviva 3mg i.v. every 3 months.
- Trial name
- NCT00493532
- Testing
- ibandronate [Bonviva/Boniva]
- Where
- 14 sites in Taiwan
- Sponsor
- Hoffmann-La Roche
Postmenopausal Osteoporosis
Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Usability of Abaloparatide-solid Microstructured Transdermal System (sMTS) in Postmenopausal Women With Low Bone Mineral Density (BMD)
This was an open-label, single-center study to evaluate the usability of abaloparatide-sMTS by participants with low BMD.
- Trial name
- NCT04366726
- Testing
- abaloparatide-sMTS
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Radius Health, Inc.
Osteopenia, Osteoporosis
Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral Density
This study is designed to provide information on the safety, tolerability, pharmacokinetics (PK) and bone biomarker response following multiple BPS804 administration in multiple dosing regimens.
- Trial name
- NCT01406548
- Testing
- BPS804 20mg/Kg
- Where
- 5 sites in United States
- Volunteers
- 44 people
- Sponsor
- Ultragenyx Pharmaceutical Inc
Osteoporosis, Osteoporosis, Postmenopausal
A Study to Evaluate Food Effect on ONO-5920/YM529 Intermittent Formulation
The aim of the study is to evaluate the effects of food intake on the plasma concentration profile of YNO-5920/YM529 in post menopausal women.
- Conditions
- Osteoporosis, Osteoporosis, Postmenopausal, Bone Diseases
- Trial name
- NCT00965978
- Testing
- ONO-5920 / YM529
- Where
- Japan
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Postmenopausal Osteoporosis
A Study to Evaluate and Compare Alendronate and Risedronate on Bone Mineral Density in Women With Postmenopausal Osteoporosis (MK-0217-211)
This study is to evaluate and compare the effects of Alendronate and Risedronate to treat women with postmenopausal osteoporosis.
- Trial name
- FACT (NCT00092014)
- Testing
- Alendronate, Risedronate 35 mg, Elemental Calcium
- Volunteers
- 1,053 people
- Sponsor
- Organon and Co
Osteoporosis
Study Evaluating TSE-424/Placebo/Raloxifene in Preventing Osteoporosis in Postmenopausal Women
The purpose of this study is to determine whether TSE-424 (bazedoxifene acetate), an investigational drug, is safe and effective in the prevention of osteoporosis in postmenopausal women.
- Trial name
- NCT00481169
- Testing
- Bazedoxifene Acetate (TSE-424)
- Volunteers
- 1,742 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Osteoporosis, Postmenopausal
Risedronate in the Prevention of Osteoporosis in Postmenopausal Women
Primary Objective: To demonstrate that risedronate 35-mg once weekly is more efficacious than placebo in increasing or maintaining bone mineral density (BMD) of the lumbar spine after 1 year of treatment in women who are…
- Trial name
- NCT00402441
- Testing
- Risedronate (HMR4003)
- Where
- United States
- Volunteers
- 260 people
- Sponsor
- Sanofi
Postmenopausal Osteoporosis
Study of Post Menopausal Osteoporosis (PMO) Among Gynecology Outpatients in Pakistan
This observational study will provide an opportunity to document local patterns of susceptibility, patient profile, and usefulness of screening in postmenopausal patients coming to gynecology outpatient clinics in Pakistan.
- Trial name
- NCT02422069
- Where
- 8 sites in Pakistan
- Volunteers
- 624 people
- Sponsor
- Hoffmann-La Roche
Postmenopausal Osteoporosis
Efficacy and Safety of Actonel® After Denosumab Discontinuation in Postmenopausal Osteoporosis Women
To evaluate the effect of 1 year of risedronate treatment on the prevention of bone loss after denosumab discontinuation in denosumab-treated post-menopausal osteoporosis for a year
- Trial name
- NCT05630768
- Testing
- Risedronate Sodium 35 MG [Actonel], Calcium Vitamin D combination
- Where
- South Korea
- Volunteers
- 149 people
- Sponsor
- Dong-A ST Co., Ltd.
Post-Menopausal Osteoporosis
BONCURE Study: A Study of Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis on Bisphosphonate Therapy.
This single arm study will assess participant preference for monthly Bonviva, versus daily or weekly alendronate or risedronate, in the treatment of postmenopausal osteoporosis.
- Trial name
- NCT00545779
- Testing
- Ibandronate
- Where
- 32 sites in Albania, Bosnia and Herzegovina and 4 more
- Volunteers
- 677 people
- Sponsor
- Hoffmann-La Roche
Osteoporosis, Postmenopausal
Effect of Alendronate 70mg Formulation on Bone Turnover Markers and Patient Reported Outcomes
Compare the data obtained with two formulations of alendronate 70 mg (tablets vs effervescent tablet for buffered solution) on the change in bone turnover markers, on gastric tolerance and on treatment adherence (including…
- Trial name
- NCT03435094
- Testing
- Binosto 70Mg Effervescent Tablet, Fosamax 70Mg Tablet
- Where
- 2 sites in Switzerland
- Volunteers
- 80 people
- Sponsor
- Labatec Pharma SA
Osteoporosis
CR9112792, a Follow-up of Study CR9108963
The purpose of this study is to determine whether bone mineral density has increased in a subgroup of postmenopausal osteoporotic women from study CR9108963, between 6 and 12 months following cessation of ronacaleret therapy.
- Trial name
- NCT00891553
- Testing
- DXA
- Where
- 3 sites in Denmark, Norway
- Volunteers
- 171 people
- Sponsor
- GlaxoSmithKline
Postmenopausal Osteoporosis
A Study of Monthly Risedronate for Osteoporosis
The purpose of this trial is to study the efficacy of a single-dose monthly dosing regimen as compared to the standard daily dosing regimen of risedronate 5 mg daily.
- Trial name
- NCT00247273
- Testing
- risedronate
- Where
- 49 sites in United States, Argentina and 12 more
- Volunteers
- 1,294 people
- Sponsor
- Warner Chilcott
Osteoporosis
Calcium Supplementation in Postmenopausal Women
This study is evaluating the effects of calcium supplementation on the efficacy and safety of recombinant parathyroid hormone (ALX1-11) in postmenopausal women with osteoporosis.
- Trial name
- CAP (NCT00172172)
- Testing
- PTH/Calcium
- Where
- 27 sites in United States, Argentina and 1 more
- Volunteers
- 374 people
- Sponsor
- Shire
Osteoporosis, Postmenopausal
Denosumab China Phase III Study
This study is to evaluate the efficacy and safety of denosumab 60 milligrams (mg) for 12 month treatment in Chinese postmenopausal women with osteoporosis at increased risk of fracture.
- Trial name
- NCT02014467
- Testing
- Denosumab, Elemental Calcium, Vitamin D
- Where
- 8 sites in China
- Volunteers
- 486 people
- Sponsor
- GlaxoSmithKline
Osteoporosis, Postmenopausal
Julina Post-marketing Surveillance for Climacteric Symptoms in Japan
This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Julina for postmenopausal osteoporosis.
- Trial name
- JULINA-CLIMA (NCT01386281)
- Testing
- E2 transdermal (Julina, BAY86-5435)
- Where
- Japan
- Volunteers
- 506 people
- Sponsor
- Bayer